NEW YORK, Dec. 8, 2020 /PRNewswire/ -- EC Mergers
& Acquisitions ("EC M&A") is pleased to confirm the sale of
ARTeSYN BioSolutions ("ARTeSYN")
ARTeSYN is a manufacturer of innovative single-use solutions for
the downstream bioprocessing industry. The Company is growing
rapidly, led by the success of its single-use chromatography and
filtration systems which are considered the gold standards in
downstream bioprocessing due to their performance, automation and
low hold-up volumes. ARTeSYN's suite of single-use solutions have
been created with the goal of enabling abundance in medicine by
allowing 10x greater efficiency in biologics manufacturing. Over
the past decade, ARTeSYN has established downstream processing
leadership with a suite of state of the art single-use systems for
chromatography, filtration, continuous manufacturing and
media/buffer prep workflows. In addition, the Company has
integrated unique flow path assemblies to deliver highly
differentiated, low hold-up volume systems that minimize product
loss during processing. ARTeSYN's product portfolio also includes
single-use valves with fully disposable valve liners, XO® skeletal
supports and a hybrid small parts offering for de-bottlenecking
traditional facilities. The Company is headquartered in
Waterford, Ireland with additional
locations in the United States and
Estonia.
Repligen Corporation (NASDAQ: RGEN) is a global life sciences
company that develops and commercializes highly innovative
bioprocessing technologies and systems that increase efficiencies
in the process of manufacturing biological drugs. Repligen's
mission is to inspire advances in bioprocessing for
biopharmaceutical drug developers and contract development and
manufacturing organizations (CDMOs) worldwide.
Michael Gagne founder of ARTeSYN
said, "We were thrilled with the opportunity to partner with EC
M&A on this transaction. EC M&A patiently and
professionally supported us in our evaluation of numerous different
offers and opportunities, including potential capital raises,
partnership with various growth equity funds, and tremendous offers
from various strategic acquirers. In the end, with EC M&A's
support and counsel, we moved forward with Repligen Corporation. We
believe Repligen is the perfect partner to continue the development
of ARTeSYN BioSolutions and pursue my goal of enabling abundance in
medicine."
The transaction totals $200M,
$130M of which will be paid in cash
and $70M in Repligen common stock.
ARTeSYN is projected to generate approximately $30M in pro forma revenue in 2020, representing
6x-7x 2020e revenue. The business is expected to contribute
approximately $33M-36M of revenue in 2021E.
About EC Mergers & Acquisitions
EC M&A is a
premier middle-market advisory firm, having advised on over 275
completed life sciences and industrial technologies transactions.
Since 1992, we have developed strong relationships with many of the
most innovative companies in biopharma technologies, life sciences,
medical devices, industrial technologies, and digital solutions.
Our focus is generating highly compelling valuations by virtue of
our deep domain expertise and genuine global buyer access for
middle market life sciences and industrial technology
transactions. EC M&A offers global, seamless client
coverage and senior-level attention across our offices in
New York, Chicago, London, Paris, Frankfurt, Prague, Zurich, Milan, Beijing and Hong
Kong. www.ec-ma.com
Contact
Richard
Hale
+44 (0) 207 665 6869
richard.hale@ec-ma.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ec-mergers--acquisitions-advised-artesyn-on-its-sale-to-repligen-301188629.html
SOURCE EC M&A